Please assess the completion status of the following clinical trial:

Trial Title: Neurofilaments for NEDA Assessing in MS

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS).~2. Age 18-55 years.~3. EDSS score between 0-5.5.~4. Commencing Alemtuzumab therapy at Neurology Infusion and Planned Investigation Unit, The Royal London Hospital, Ward 11D~Exclusion Criteria:~1. A diagnosis of Secondary Progressive MS (SPMS) or other forms of progressive MS.~2. Those unable to comply with study requirement

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).